Description
A new cancer drug, ibrutinib (Imbruvica), developed by pharmaceutical company J&J, is significantly more effective than standard chemotherapy for leukemia. This is proven by the results of clinical trials published in The Daily Mail.
In the study, some patients with chronic lymphocytic leukemia received ibrutinib, and some patients received chemotherapy. It turned out that the survival rate in the first group was 90%, in the chemotherapy group - 81%. The researchers note that four out of ten participants in the ibrutinib group and four out of one hundred in the chemotherapy group had a remission rate.
It should also be noted that patients responded more quickly to ibrutinib than to chemotherapy. Another advantage of the new drug over chemotherapy is that its use causes fewer side effects.
Scientists believe that ibrutinib could replace standard chemotherapy. It is especially recommended for patients who have developed resistance to chemotherapy. When we talk about the price of ibrutinib in the USA, it is the most expensive cancer drug.
Indications for use
Ibrutinib should be taken once a day with a glass of water at around the same time each day. The ibrutinib capsule should be swallowed whole with water; Do not open, break or chew the capsule. Imbruvica should not be taken with grapefruit juice.
Treatment of adult patients with relapsed or refractory mantle cell lymphoma.
Treatment of adult patients with chronic lymphocytic leukemia who have received at least one line of therapy, or patients with 17p deletion or TP53 mutation in whom chemoimmunotherapy is contraindicated as first-line therapy.
Use during pregnancy and breastfeeding
Use during pregnancy and breastfeeding is contraindicated.
Use in case of liver dysfunction
Contraindication: severe kidney damage; severe liver dysfunction (class C according to the Child-Pugh scale).
Use in renal impairment
Patients with mild or moderately severe renal impairment (creatinine clearance more than 30 ml/min) do not require dose adjustment. No data are currently available in patients with severe renal impairment or on dialysis.
Contraindication: severe kidney damage, dialysis patients.
Use in children
Contraindicated in children and adolescents under 18 years of age.
Use in elderly patients
The need for age-related dose adjustment has not been confirmed.
Side effects
Data on side effects of ibrutinib are based on data obtained during clinical trials and during the post-marketing period.
The most commonly observed side effects were diarrhea, neutropenia, bleeding (eg, bruising), musculoskeletal pain, vomiting, rash, and fever. The most frequently observed III. and IV. grade AEs were: neutropenia, pneumonia, thrombocytopenia, and febrile neutropenia.
Adverse reactions related to ibrutinib treatment in patients with B-cell malignancies and adverse reactions observed during the post-marketing period are summarized in Table 2 and listed by system organ class and frequency distribution. Within each frequency grouping, side effects are listed in order of decreasing seriousness.
Storage
Store at a maximum temperature of 25 °C, protected from light. Keep out of reach of children.
Ibrutinib Exporter and Supplier
We are committed to solving this problem by providing Ibrutinib at wholesale prices. The price of ibrutinib in Malaysia, UAE is also very high, but Medixo Center offers Ibrutinib at wholesale price because we understand the importance of affordable options. Patients can save a lot of money by taking advantage of these discounted prices. They may be able to use their savings to meet other needs. You can buy ibrutinib online from us at an unbeatable price . If you want to contact us, please call or send a message via WhatsApp/Viber/Telegram at +91-9999344593. You can also buy Email us at info@medixocentre.com. We promise to offer you the best price. We ship to USA, UAE, UK, China, Philippines, Thailand, Malaysia, Singapore, Colombia, Italy, Australia, France, Trinidad & Tobago, Chile, Peru, Brazil, Cambodia, Venezuela, Vietnam, Ecuador , to South Korea, South Africa, Nigeria, Hong Kong, Russia, Japan and many other countries.
